07:51 AM EDT, 07/01/2025 (MT Newswires) -- Atai Life Sciences ( ATAI ) said Tuesday it has signed subscription agreements to raise $50 million through a private placement of about 18.3 million ordinary shares with a nominal value of 0.10 euro ($0.12) per share and pre-funded warrants to purchase roughly 4.6 million additional shares.

The financing round was co-led by Ferring Ventures and Apeiron Investment, the family office of Atai Founder and Chairman Christian Angermayer, the company said. Other participants included Ally Bridge and ADAR1, the company added.

Atai said it will use the net proceeds for corporate purposes and to advance its clinical programs.

The deal is expected to close in Q3, subject to customary conditions, including the expiration of the Hart-Scott-Rodino Antitrust Improvements Act waiting period related to Apeiron's involvement, the company said.

Shares of Atai were rising more than 12% in recent premarket activity Tuesday.